Skip to main content

Table 3 Subgroups for which adjuvant therapy benefit patients more after propensity score matching

From: Real-world efficacy of adjuvant therapy for totally resected stage I lung adenocarcinoma patients with pathological high-risk factors: propensity score analysis

Variables

Univariate analyses HR (95% CI)

P value

Female

0.33 (0.13–0.84)

0.019

Non-smoker

0.35 (0.16–0.79)

0.012

Multiple risk factors

0.27 (0.11–0.70)

0.007

Stage IB

0.38 (0.17–0.81)

0.013

≤ 50 years

0.20 (0.04–0.92)

0.039

>2 and ≤ 3 cm

0.26 (0.08–0.78)

0.017

Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us